C3 mutation-associated atypical hemolytic uremic syndrome with severe renal dysfunction and hypertensive emergency successfully treated with ravulizumab and sacubitril/valsartan: a case report.

Abstract excerpt

BACKGROUND: Atypical hemolytic uremic syndrome (aHUS) is a rare complement-mediated thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. Although C5 inhibitors, such as eculizumab and ravulizumab, have markedly improved outcomes, renal recovery remains limited in cases complicated by hypertensive emergency (HE) or malignant hypertension, likely...

Topics

Join the communities discussing this publication.

• Aminobutyrates
• Angiotensin Receptor Antagonists
• Antibodies, Monoclonal, Humanized
• Atypical Hemolytic Uremic Syndrome